Cargando…
Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer
Stathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly in breast cancer, have suggested that stathmin may additionally be a predictive marker for response to paclitaxel. We first evaluated the response to paclitaxel in endometrial cancer cel...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934991/ https://www.ncbi.nlm.nih.gov/pubmed/24587245 http://dx.doi.org/10.1371/journal.pone.0090141 |
_version_ | 1782305138997723136 |
---|---|
author | Werner, Henrica M. J. Trovik, Jone Halle, Mari K. Wik, Elisabeth Akslen, Lars A. Birkeland, Even Bredholt, Therese Tangen, Ingvild L. Krakstad, Camilla Salvesen, Helga B. |
author_facet | Werner, Henrica M. J. Trovik, Jone Halle, Mari K. Wik, Elisabeth Akslen, Lars A. Birkeland, Even Bredholt, Therese Tangen, Ingvild L. Krakstad, Camilla Salvesen, Helga B. |
author_sort | Werner, Henrica M. J. |
collection | PubMed |
description | Stathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly in breast cancer, have suggested that stathmin may additionally be a predictive marker for response to paclitaxel. We first evaluated the response to paclitaxel in endometrial cancer cell lines before and after stathmin knock-down. Subsequently we investigated the clinical response to paclitaxel containing chemotherapy in metastatic endometrial cancer in relation to stathmin protein level in tumors. Stathmin level was also determined in metastatic lesions, analyzing changes in biomarker status on disease progression. Knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel. In clinical samples, high stathmin level was demonstrated to be associated with poor response to paclitaxel containing chemotherapy and to reduced disease specific survival only in patients treated with such combination. Stathmin level increased significantly from primary to metastatic lesions. This study suggests, supported by both preclinical and clinical data, that stathmin could be a predictive biomarker for response to paclitaxel treatment in endometrial cancer. Re-assessment of stathmin level in metastatic lesions prior to treatment start may be relevant. Also, validation in a randomized clinical trial will be important. |
format | Online Article Text |
id | pubmed-3934991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39349912014-03-04 Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer Werner, Henrica M. J. Trovik, Jone Halle, Mari K. Wik, Elisabeth Akslen, Lars A. Birkeland, Even Bredholt, Therese Tangen, Ingvild L. Krakstad, Camilla Salvesen, Helga B. PLoS One Research Article Stathmin is a prognostic marker in many cancers, including endometrial cancer. Preclinical studies, predominantly in breast cancer, have suggested that stathmin may additionally be a predictive marker for response to paclitaxel. We first evaluated the response to paclitaxel in endometrial cancer cell lines before and after stathmin knock-down. Subsequently we investigated the clinical response to paclitaxel containing chemotherapy in metastatic endometrial cancer in relation to stathmin protein level in tumors. Stathmin level was also determined in metastatic lesions, analyzing changes in biomarker status on disease progression. Knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel. In clinical samples, high stathmin level was demonstrated to be associated with poor response to paclitaxel containing chemotherapy and to reduced disease specific survival only in patients treated with such combination. Stathmin level increased significantly from primary to metastatic lesions. This study suggests, supported by both preclinical and clinical data, that stathmin could be a predictive biomarker for response to paclitaxel treatment in endometrial cancer. Re-assessment of stathmin level in metastatic lesions prior to treatment start may be relevant. Also, validation in a randomized clinical trial will be important. Public Library of Science 2014-02-25 /pmc/articles/PMC3934991/ /pubmed/24587245 http://dx.doi.org/10.1371/journal.pone.0090141 Text en © 2014 Werner et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Werner, Henrica M. J. Trovik, Jone Halle, Mari K. Wik, Elisabeth Akslen, Lars A. Birkeland, Even Bredholt, Therese Tangen, Ingvild L. Krakstad, Camilla Salvesen, Helga B. Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer |
title | Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer |
title_full | Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer |
title_fullStr | Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer |
title_full_unstemmed | Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer |
title_short | Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer |
title_sort | stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934991/ https://www.ncbi.nlm.nih.gov/pubmed/24587245 http://dx.doi.org/10.1371/journal.pone.0090141 |
work_keys_str_mv | AT wernerhenricamj stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT trovikjone stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT hallemarik stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT wikelisabeth stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT akslenlarsa stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT birkelandeven stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT bredholttherese stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT tangeningvildl stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT krakstadcamilla stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer AT salvesenhelgab stathminproteinlevelapotentialpredictivemarkerfortaxanetreatmentresponseinendometrialcancer |